My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

4.900 +0.040 (+0.82%)
Streaming Delayed Price Updated: 1:58 PM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Looking Into Precision BioSciences's Return On Capital Employed
 
Via Benzinga
Preview: Precision BioSciences's Earnings
 
Via Benzinga
Precision BioSciences Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference
From Precision BioSciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
From Precision BioSciences, Inc.
Via Business Wire
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones
From Precision BioSciences
Via Business Wire
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
From Precision BioSciences, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Change to its Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
Coinbase To $80? Plus Deutsche Bank Cuts PT On This Stock By 80%
Citigroup cut the price target on Coinbase Global, Inc. (NASDAQ: COIN) from $105 to $80. Citigroup analyst Peter Christiansen maintained a Buy rating on the stock. Coinbase shares rose 2.1% to $46.95... 
Via Benzinga
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences's Earnings Outlook
Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.